Studies of the Antitumor Activity of Iodacetate in the Liposomal Form

Metabolic reprogramming has become the new hallmark of cancer. Carbohydrate metabolism is a key component of metabolic transformations in tumors. To date, many therapeutic agents have been identified that target proteins and enzymes involved in glucose transport and metabolism, with promising result...

Full description

Saved in:
Bibliographic Details
Published in:Doklady. Biochemistry and biophysics 2022-12, Vol.507 (1), p.278-282
Main Authors: Korshunov, D. A., Buldakov, M. A., Sereda, E. E., Bukterov, M. V., Milto, I. V., Kondakova, I. V.
Format: Article
Language:English
Subjects:
Animal models
Animals
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Antitumor activity
Biochemistry
Biological and Medical Physics
Biomedical and Life Sciences
Biophysics
Carbohydrate metabolism
Cell culture
Cell Line, Tumor
Glucose metabolism
Glucose transport
Glycolysis
Growth inhibition
Iodoacetates
Life Sciences
Liposomes - pharmacology
Molecular Biology
Neoplasms - drug therapy
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Metabolic reprogramming has become the new hallmark of cancer. Carbohydrate metabolism is a key component of metabolic transformations in tumors. To date, many therapeutic agents have been identified that target proteins and enzymes involved in glucose transport and metabolism, with promising results in cell culture studies and animal tumor models. In our studies, we found that the most promising among them is the glycolysis inhibitor iodoacetate. The study of this agent showed that iodoacetate in liposomal form has the best performance. With a course introduction, its antimetastatic and antitumor activity reached significant indices of growth inhibition. At the same time, liposomes with iodoacetate had an almost completely safe toxicological profile compared to the independent form and, as a result, have great potential in polychemotherapy.
ISSN:1607-6729
1608-3091
DOI:10.1134/S1607672922060059